Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative mFOLFIRINOX vs Gemcitabine/Nab-Paclitaxel in Resectable Pancreatic Cancer
NCT02562716Phase 2Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Jan 2016
- Primary completion
- May 2020
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fluorouracil, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, oxaliplatin, gemcitabine and paclitaxel in pancreatic adenocarcinoma (PDAC), sponsored by SWOG Cancer Research Network. Primary endpoint: Overall Survival at 2 years. Started Jan 2016; status: completed.
02
Drugs
fluorouracilirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumaboxaliplatingemcitabinepaclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02562716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02562716.